Revolution Medicines, Inc. (ETR:42Z)
Germany · Delayed Price · Currency is EUR | Market Cap | 37.21B +383.6% |
| Revenue (ttm) | n/a |
| Net Income | -1.55B |
| EPS | -7.81 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,418 |
| Open | 170.50 |
| Previous Close | 170.00 |
| Day's Range | 165.35 - 170.50 |
| 52-Week Range | 122.85 - 193.45 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 5, 2026 |
About Revolution Medicines
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236)... [Read more]
News
Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer
REDWOOD CITY, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innov...
Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer
REDWOOD CITY, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering inno...
New drug shows promise for lung cancer
Revolution Medicines CEO Dr. Mark Goldsmith discusses the clinical trial results from Rasonque on ‘FBN's Wall Street.'
Two scientists made huge bets on 'impossible' cancer treatments. They're finally paying off.
2026 is the year of the cancer breakthrough, with innovations from Revolution Medicines and Moderna. "I'm almost tired of saying paradigm shift, but I haven't figured out a new phrase," one expert sai...
New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines' RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer
REDWOOD CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering inno...
Why the Drugmaker Behind a Pancreatic Cancer Breakthrough Stayed Independent
Revolution Medicines attracted takeover interest but decided to go it alone. This week's FDA approval of its pancreatic cancer pill is the payoff.
Revolution Medicines Transcript: FDA announcement
FDA approved RASONQUE (daraxonrasib) as the first targeted therapy for metastatic pancreatic cancer, based on phase III data showing a 60% reduction in risk of death and improved quality of life. The drug is available immediately in the U.S., with robust commercialization and patient support in place.
Revolution Medicines Slides: FDA announcement
Revolution Medicines has posted slides in relation to its latest quarterly earnings report, which was published on August 26, 2026.
Revolution Medicines Press release: FDA announcement
Revolution Medicines issued a press release on August 26, 2026, disclosing material business information to investors.
U.S. FDA Approves Revolution Medicines' RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
This release contains multimedia assets available for download here
Revolution Medicines Wins FDA Approval for Pancreatic Cancer Pill. What It Means for the Stock.
Daraxonrasib, the pill touted by a former member of Congress and cancer patient as a ‘miracle drug,' has been granted approval in patients with pancreatic adenocarcinoma.
The FDA approved a new drug from Revolution Medicines that promises to transform treatment of pancreatic cancers that kill many patients within a year of diagnosis
The FDA approved a therapy from Revolution Medicines that slows a cancer that kills 7 of out 8 patients within five years.
Revolution Medicines gets FDA nod for targeted pancreatic cancer drug
The U.S. Food and Drug Administration on Wednesday approved Revolution Medicines' targeted drug for adults with metastatic pancreatic cancer who have received prior treatment or cannot receive com...
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration
SAN CARLOS, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, and Revolution Medicines, Inc. (Nas...
Revolution Medicines Earnings Call Transcript: Q2 2026
Q2 2026 saw transformational clinical and regulatory progress, with daraxonrasib showing paradigm-shifting results in pancreatic cancer and rapid expansion of access programs. Financially, strong liquidity supports increased investment in manufacturing, clinical, and commercial readiness, while pivotal trials advance in pancreatic and lung cancer.
Revolution Medicines Earnings release: Q2 2026
Revolution Medicines released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Revolution Medicines Quarterly report: Q2 2026
Revolution Medicines has published its Q2 2026 quarterly earnings report on August 5, 2026.
Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
REDWOOD CITY, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted c...
Revolution Medicines Slides: Corporate presentation
Revolution Medicines has posted slides in relation to its latest quarterly earnings report, which was published on August 1, 2026.
Revolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026
REDWOOD CITY, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted c...
Revolution Medicines' New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer
REDWOOD CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted c...
European Medicines Agency Expedites Assessment of Revolution Medicines' Daraxonrasib Under Phased Review Process
REDWOOD CITY, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted c...
EMA fast-tracks review of Revolutions' experimental pancreatic cancer pill
The European Medicines Agency said on Tuesday it has begun a rolling review of Revolution Medicines' experimental treatment for patients with metastatic pancreatic cancer.
Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
REDWOOD CITY, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted c...
Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
REDWOOD CITY, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announc...